Latest Articles about NUVA

HAE Beats on Earnings, Revs in Line - Analyst Blog

Zacks Equity Research — Fri, 03 May 2013 23:32:57 Z

Haemonetics Corporation ( HAE ) reported net income of $12.6 million or earnings per share (EPS) of 24 cents in the fourth quarter of fiscal 2013, down 29% and 31% year over year,

LIFE Beats Earnings, Margins Low - Analyst Blog

Zacks Equity Research — Fri, 03 May 2013 22:29:36 Z

Following the announcement of the proposed acquisition deal with Thermo Fisher ( TMO ), Life Technologies Corporation ( LIFE ) reported its first-quarter 2013 earnings per share (EPS)

Symmetry 1Q Earnings Disappoint - Analyst Blog

Zacks Equity Research — Fri, 03 May 2013 16:31:01 Z

Symmetry Medical 's ( SMA ) first-quarter 2013 adjusted earnings per share (EPS) of 4 cents missed the Zacks Consensus Estimate of 15 cents. Adjusted earnings exclude one-time items

Hanger 1Q Earnings Beat - Analyst Blog

Zacks Equity Research — Thu, 02 May 2013 23:27:40 Z

Hanger Inc. 's ( HGR ) adjusted earnings per share (EPS) of 28 cents for the first quarter of 2013 beat the Zacks Consensus Estimate of 25 cents. It also exceeded the year-ago first quarter

Haemonetics Closes Hemerus Acquisition - Analyst Blog

Zacks Equity Research — Thu, 02 May 2013 21:47:31 Z

Recently, Haemonetics ( HAE ) completed the acquisition of Hemerus Medical, a Minn.-based company that develops technologies for the collection of whole blood, and processing and storage of

Earnings Beat at Hospira - Analyst Blog

Mark Vickery — Wed, 01 May 2013 21:10:01 Z

Hospira Inc. 's ( HSP ) first quarter 2013 adjusted earnings of 52 cents per share beat the Zacks Consensus Estimate of 44 cents. Higher-than-expected revenues led to the earnings beat.

Qiagen Acquires IngenuitySystems - Analyst Blog

Zacks Equity Research — Tue, 30 Apr 2013 22:50:58 Z

In an attempt to manage its growing volume of genomic data, Qiagen ( QGEN ) recently acquired Calif.-based privately owned company, Ingenuity Systems, Inc. Through the acquisition, Qiagen

Reiterate Varian at Neutral - Analyst Blog

Zacks Equity Research — Tue, 30 Apr 2013 22:50:26 Z

On Apr 29, we retained Varian Medical Systems, Inc. ( VAR ) at Neutral after the company reported results for the second quarter fiscal 2013. Why the Reiteration? On April 24, Varian

Covidien's 2Q Earnings Beat - Analyst Blog

Zacks Equity Research — Fri, 26 Apr 2013 23:40:01 Z

Covidien plc. 's ( COV ) adjusted earnings per share (EPS) from continuing operations of $1.12 for the second quarter of fiscal 2013 beat the Zacks Consensus Estimate of $1.10 by 1.8%.

BSX Beats Y/Y Earnings, Guides Low - Analyst Blog

Zacks Equity Research — Fri, 26 Apr 2013 00:12:11 Z

Boston Scientific ( BSX ) reported adjusted earnings per share (after considering certain adjustments other than amortization expense) ("EPS") of 10 cents in the first quarter of

Stryker's 1Q Earnings Beat Est.; Sales Lag - Analyst Blog

Zacks Equity Research — Thu, 25 Apr 2013 23:13:14 Z

Stryker Corporation 's ( SYK ) adjusted earnings per share (EPS) of $1.03 increased 4.0% year over year in the first quarter of 2013. It beat the Zacks Consensus Estimate by 2 cents.

Zimmer Beats Earnings, Misses Revenue - Analyst Blog

Zacks Equity Research — Thu, 25 Apr 2013 20:06:01 Z

Zimmer Holdings ( ZMH ) reported adjusted earnings at $1.41, up 8.5% year over year, as well as a penny ahead of the Zacks Consensus Estimate. However, after including one-time items,

Edwards Lags on Earnings & Rev - Analyst Blog

Zacks Equity Research — Wed, 24 Apr 2013 18:14:58 Z

Edwards Lifesciences Corporation's ( EW ) first-quarter 2013 adjusted earnings per share (EPS) came in at 72 cents, up 35.8% year over year, but lagging the Zacks Consensus Estimate of 76

AmSurg's Rev and Earnings In Line - Analyst Blog

Zacks Equity Research — Wed, 24 Apr 2013 17:30:01 Z

AmSurg Corp. 's ( AMSG ) first-quarter 2013 adjusted earnings per share ("EPS") of 52 cents were 2 cents ahead of the year-ago quarter EPS and in line with the Zacks Consensus

Abbott - Epizyme Collaborate - Analyst Blog

Zacks Equity Research — Wed, 24 Apr 2013 02:10:27 Z

Abbott Laboratories ( ABT ) recently announced a strategic deal with Epizyme, Inc. for the development of a molecular companion diagnostic test for use with EPZ-5676. EPZ-5676 is being